1 A circulating proteome-informed prognostic model of COVID-19 disease activity that relies on

2 routinely available clinical laboratories

3

4 William Ma^{1,*}, Antoine Soulé^{1,*}, Karine Tremblay², Simon Rousseau^{3, +}, and Amin Emad^{1,4, +}

* These authors contributed equally.

¹ Department of Electrical and Computer Engineering, McGill University, Montréal, QC, Canada

- 5 ² Pharmacology-physiology Department, Faculty of Medicine and Health Sciences, Université de
- 6 Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux
- 7 du Saguenay-Lac-Saint-Jean, Saguenay, QC, Canada; CRCHUS, Sherbrooke, Canada.

³ The Meakins-Christie Laboratories at the Research Institute of the McGill University Heath Centre Research Institute, & Department of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada

⁴ Mila, Quebec AI Institute, Montréal, QC, Canada

8

+ Co-corresponding Authors:

Amin Emad,

755 McConnell Engineering Building, 3480 University Street, Montreal H3A 0E9, Canada Email: amin.emad@mcgill.ca

Simon Rousseau, RI-MUHC, E M3.2244, 1001 Décarie, Montréal H4A 3J1, Canada, Email: simon.rousseau@mcgill.ca

10 Abstract

11 A minority of people infected with SARS-CoV-2 will develop severe COVID-19 disease. To help 12 physicians predict who is more likely to require admission to ICU, we conducted an unsupervised 13 stratification of the circulating proteome that identified six endophenotypes (EPs) among 731 14 SARS-CoV-2 PCR-positive hospitalized participants in the Biobangue Québécoise de la COVID-19, 15 with varying degrees of disease severity and times to intensive care unit (ICU) admission. One 16 endophenotype, EP6, was associated with a greater proportion of ICU admission, ventilation 17 support, acute respiratory distress syndrome (ARDS) and death. Clinical features of EP6 included increased levels of C-reactive protein, D-dimers, interleukin-6, ferritin, soluble fms-like tyrosine 18 19 kinase-1, elevated neutrophils, and depleted lymphocytes, whereas another endophenotype 20 (EP5) was associated with cardiovascular complications, congruent with elevated blood 21 biomarkers of cardiovascular disease like N-terminal pro B-type natriuretic peptide (NT-proBNP), Growth Differentiation Factor-15 (GDF-15), and Troponin T. Importantly, a prognostic model 22 23 solely based on clinical laboratory measurements was developed and validated on 903 patients 24 that generalizes the EPs to new patients recruited across all pandemic waves (2020-2022) and 25 create new opportunities for automated identification of high-risk groups in the clinic. Thus, this 26 novel way to address pathogenesis that leverages detailed phenotypic information but relies on 27 routinely available information in the clinic to favor translation may find applications in other 28 diseases beyond COVID-19.

29

31 Introduction

32 An important challenge facing respirologists and critical care physicians is the heterogeneity in 33 outcome following SARS-CoV-2 infections. A minority of people infected with SARS-CoV-2 will 34 develop a severe form of coronavirus disease 2019 (COVID-19) requiring hospitalization and 35 respiratory support. Defining the molecular mechanisms related to specific severe outcomes is 36 important to identify treatable traits and improve the survival of critically ill patients. Successfully reaching this precision medicine goal requires a more granular definition of the underlying 37 38 pathophysiology. A symptom-based method to discover molecular mechanisms of the disease is 39 inherently confounded by the fact that the same higher-level condition, such as severe COVID-40 19 disease, can be produced by several different molecular mechanisms, a phenomenon termed 41 the "many-one" limitation (1). Recent advances in computing strategies, such as machine 42 learning, have enabled the development of methods that help overcome this limitation by, 43 instead of using symptoms, starting from molecular profiles to define endophenotypes, i.e., 44 subgroups of individuals who are inapparent to traditional classification methods but share a 45 common set of molecular factors that can lead to identification of treatable traits (2-4). Current 46 investigations of endophenotypes in COVID-19 have mainly relied on supervised approaches 47 using fixed outcomes (such as disease severity) and integrating clinical variables at the onset (5). 48 We hypothesize that using an unsupervised approach and exploiting a rich molecular dataset can 49 provide novel mechanistic insights into the pathobiology of severe COVID-19 that can help 50 physicians improve diagnosis, prognosis, and clinical management.

51

52 This study identified six endophenotypes linked to diverse clinical trajectories of COVID-19 using 53 the extensive molecular phenotyping of a cohort of 731 SARS-CoV-2 positive hospitalized patients 54 from the Biobanque Québécoise de la COVID-19 (BQC19, www.quebeccovidbiobank.ca) (6), a 55 prospective observational cohort of SARS-CoV-2-positive and negative participants recruited in 56 the province of Québec, Canada, to improve our understanding of COVID-19 pathobiology and 57 our capacity to alter disease outcomes. The molecular signature of each endophenotype was 58 used to build a prognostic model of disease severity that generalizes the EPs to new patients and 59 was validated on a separate group of 903 patients. This prognostic model solely utilizes clinical laboratory measurements, creating the possibility of automated identification of high-risk groups 60 61 in the clinic.

- 62
- 63 Results

64 Unsupervised clustering of SARS-CoV-2-positive hospitalized BQC19 participants reveal 65 endophenotypes associated with varying disease severity

We aimed to identify endophenotypes of COVID-19, based on the circulating proteome of 66 67 patients, in a cohort of SARS-CoV-2 positive hospitalized participants in the BQC19 (Table 1) using an unsupervised approach. Figure S1 shows the distribution of the patient hospital admission 68 69 dates and the corresponding waves of COVID-19 infection as defined by National Institute of 70 Public Health of Quebec (INSPQ, https://www.inspq.qc.ca/covid-19). Consensus agglomerative clustering was performed on participants (n = 731, Table 1) for whom the circulating proteome 71 72 was measured using a multiplex SOMAmer affinity array (SomaLogic, ~5,000 aptamers) (7). The 73 optimal number of clusters (k = 6) was identified first using two criteria: Akaike's Information

Criteria (AIC) and Bayesian Information Criteria (BIC) (Figure 1A). Then, consensus agglomerative clustering (Euclidean distance and Ward linkage) (8, 9) using 1000 bootstrap subsamples of the participants was performed to obtain six robust clusters (Figure 1, Figures S2 and S3). The distribution of Rand-Index, showing the concordance between each one of the 1000 subsampled clusterings and the final consensus clustering, is provided in Figure S2B (mean Rand-Index = 0.823), reflecting a high degree of consistency and robustness.

80

81 The clinical and pathological characteristics of patients in each endophenotype is provided in 82 Table 1. To characterize the identified endophenotypes (EPs) with respect to disease severity, we performed two-sided Fisher's exact tests to assess their enrichment (or depletion) in either of 83 84 "severe" or "deceased" outcomes. EP6 was significantly enriched in the severe/deceased 85 outcomes (Benjamini–Hochberg false discovery rate (FDR) = 1.74E-21) with either of these 86 outcomes observed in 74.6% of EP6 patients. Meanwhile, EP1 was significantly depleted in 87 severe/deceased outcomes (FDR = 1.89E-13) (Figure 2A, Table 1, Table S1) with either of these 88 outcomes observed in only 13.2% of EP1 patients. In addition, EP6 was enriched in participants 89 (a) receiving oxygen therapy (FDR = 4.23E-18), (b) receiving ventilatory support (FDR = 4.59E-18), 90 and (c) being admitted to intensive care unit (ICU) (FDR = 9.51E-28) (Figure 2A, Table 1, Table S1). 91 Kaplan–Meier analysis (10) also confirmed that the identified EPs have a distinct temporal 92 pattern of admission to ICU (multivariate logrank test P = 5.00E-30), with EP1 and EP6 having the highest and lowest probability, respectively, of not being admitted to ICU or dying prior to that 93 94 in a 40-day span since their admission to the hospital (Figure 2C). A similar pattern was also 95 observed when patients that died before admission to ICU were excluded (Figure S4, multivariate

logrank test P = 5.39E-30). A two-sided Mann–Whitney U (MWU) test showed that patients in
EP5 were generally older than other EPs (FDR = 7.73E-5), while EP3 included younger patients
(FDR = 1.53E-4). Notably, EP6 (which had the most severe patients) did not show enrichment in
older patients or individuals with high body mass index (BMI) (two-sided MWU FDR > 0.05)
(Figures 2D-F, Table 1, Table S1).

101

These analyses revealed that the unsupervised approach using the circulating proteome of the patients was able to identify endophenotypes with distinct disease characteristics and outcomes.
We identified EP6 as a group of participants with an increase in key measures of COVID-19 disease severity, including admission to ICU and the need for ventilatory support.

106

107 EP6 is enriched among BQC19 participants with acute respiratory distress syndrome

108 To better characterize all EPs with regards to different complications, we performed two-sided 109 Fisher's exact tests comparing each EP to the rest. In accordance with increased COVID-19 disease 110 severity, EP6 was enriched in several medical complications including ARDS (FDR = 1.12E-11), 111 acute kidney injury (FDR = 5.73E-8), secondary bacterial pneumonia (FDR = 2.25E-5), liver 112 dysfunction (FDR = 1.37E-3), cardiovascular complications (FDR = 1.37E-3), and bacteremia (FDR 113 = 4.28E-3) (for the full list, see Figure 3 and Table S2). Notably, the frequency of ARDS was 9% in 114 EP1 compared to 50% in EP6 making this complication a key feature of this endophenotype 115 (Figure 3, Table S2).

117 Clinical laboratories reveal that members of EP6 have increased levels of C-reactive protein, D-

118 dimers, elevated neutrophils, and depleted lymphocytes

119 To further characterize each EP, we assessed the clinical laboratory results obtained from blood 120 draws and compared them between the groups. We focused on 21 markers that were measured 121 in at least 50% of the patients of the cohort and used the summary value reported in the BQC19 122 database corresponding to the most extreme measurement among multiple blood draws (Figure 123 4A, Table S3 also includes first blood draw characteristics). Figure 3A shows the elevation and 124 depletion of these markers in the identified EPs. EP6 is characterized by abnormal values in 125 markers of inflammation (lymphopenia, total white blood cell count, neutrophilia, C-reactive 126 protein (CRP)), liver damage (alanine aminotransferase (ALT)), coagulopathy (D-dimers, low 127 hemoglobin, International Normalized Ratio (INR), and hyperglycemia (glucose). We also used 22 128 markers from the Elecsys diagnostic panel (Roche Diagnostic) to further characterize EP6, (Figure 129 4B and Table S3). This led to additional elevated and highly significant markers: (a) alpha-1 130 antitrypsin, an acute phase reactant elevated during inflammatory conditions; (b) Interleukin 6 131 (IL-6), a pleiotropic cytokine associated with systemic inflammatory response syndrome (11), 132 shown to be elevated in severe COVID-19 (12) and linked to endothelial damage and liver injury 133 (13); (c) ferritin, an iron-storage protein and acute phase reactant, elevated in COVID-19, and like 134 other hyperferritinic syndrome, associated with coagulopathy (14, 15); and (d) soluble vascular 135 endothelial growth factor (VEGF) receptor sFLT1 (soluble fms-like tyrosine kinase-1), previously shown to be associated with endothelial damage and COVID-19 severity (16). The overall 136 137 characteristics of each EP are summarized in Table 2.

139 EP5 is associated with cardiovascular complications

140 EP5 comes second in the order of severity established in Figure 2. Interestingly, it is molecularly and clinically distinct from EP6 (Figures 2-4, Table 1). A striking feature of EP5 is the increase in 141 142 markers of cardiovascular diseases, such as higher levels of N-terminal pro B-type natriuretic 143 peptide (NT-proBNP), indicative of ventricular dysfunction (17), Growth Differentiation Factor-15 144 (GDF-15) associated with cardiometabolic risk (18) and Troponin T linked to cardiac damage all 145 suggestive of high risk for cardiovascular events (19) (Figure 4B). Accordingly, this group was 146 enriched for cardiovascular complications during hospitalization (FDR = 1.46E-2, Figure 3). As 147 postulated, the unsupervised clustering was able to distinguish different types of COVID-19 148 disease trajectory.

149

150 A computational prognostic model based on blood biomarkers predicts EPs in a separate 151 validation cohort

152 Since each EP showed a clear and distinct clinical laboratory result signature based on 21 blood markers and 22 Elecsys diagnostic markers, we sought to develop a computational prognostic 153 154 model of disease severity based on these signatures. We focused on data from the first blood 155 draw (Figure 4B and S5, Table S3) and developed a nearest-centroid classifier, capable of dealing 156 with missing values, to predict EPs based on these 43 markers (see Methods for details). To test 157 the prognostic ability of this model on an independent yet similar dataset, we analyzed 903 SARS-CoV-2 positive hospitalized BQC19 participants that did not have circulating proteome data and 158 159 had not been used to identify the endophenotypes (see Figure S6 for the distribution of the 160 patient hospital admission dates). These patients were recruited across all waves of the pandemic

between March 2020 and October 2022. The clinical and pathological characteristics of patients
in each predicted endophenotype (PEP) are provided in Figure 5 and Table S4.

163

164 Our prognostic model identified 167 of these 903 patients as belonging to predicted EP6 (PEP6). 165 Fisher's exact tests showed significant enrichments of PEP6 in severe/deceased (FDR = 5.62E-21), 166 while PEP1 and PEP2 were significantly depleted in these outcomes (FDR = 5.29E-8 and FDR = 167 1.19E-8, respectively), as shown in Table S4. Like EP6, PEP6 was also significantly enriched in 168 participants (a) receiving oxygen therapy (FDR = 2.87E-13), (b) receiving ventilatory support (FDR 169 = 1.50E-13), and (c) being admitted to ICU (FDR = 1.34E-19) (Table S4). Kaplan–Meier analysis 170 also confirmed that these PEPs have a distinct temporal pattern of admission to ICU (multivariate 171 logrank test P = 1.56E-21), with PEP6 having the highest chance of being admitted to ICU (or dying 172 prior to that) in the 40-day span following admission to hospital (Figure 5B). These results suggest 173 that our prognostic model based on 43 blood biomarkers can be used to generalize the definition 174 of endophenotypes to patients for whom proteomic data is not available. Since the 21 blood 175 markers are more commonly available, we also developed a prognostic model only based on 176 these markers, which also showed strong prognostic capabilities (Figure S7). Therefore, it is 177 possible to leverage detailed molecular information on a smaller number of participants to 178 predict clinical outcomes on a larger population using routinely available information collected 179 during hospitalization.

180

181 Discussion

In this study, we have bridged the gap between the circulating proteome and routinely available blood diagnostic biomarkers, using machine learning algorithms, to prognosticate COVID-19 outcomes in hospitalized patients. The model performed on participants recruited across all the pandemic waves from 2020 to 2022, demonstrating that it performs despite mutations in infecting strains and the development of immunity. This showcases a novel analytical pipeline that can support physicians in making more informed decision on potential unfavorable trajectories early during hospitalization and adjust follow-ups and treatments accordingly.

189

190 The major strength of this study is the use of an unsupervised approach for analysis of a large 191 and well-phenotyped cohort. This broad-based approach led to the identification of six COVID-192 19 disease endophenotypes in hospitalized patients that could not be captured by simply 193 classifying the population solely based on severity, with different clinical trajectories and 194 distinguishing characteristics that are summarized in Tables 1 and 2. We identified two 195 endophenotypes with more favorable outcomes (EP1 and EP2), three endophenotypes with 196 intermediate outcomes in terms of severity (EP3, EP4 and EP5) and one endophenotype which 197 led to worst outcomes compared to all others (EP6). EP6, was associated with ARDS, the worst 198 clinical manifestation of COVID-19 that was reflected by a greater proportion of ICU admission, 199 mechanical ventilation, and severe/fatal outcomes (Figures 2 and 3). Clinical features of this 200 endophenotype were consistent with published literature, including increased levels of CRP, D-201 dimers, IL-6, ferritin, sFLT1, elevated circulating neutrophils, and reduced peripheral blood 202 lymphocytes (Figure 3, Table S3), presenting a profile associated with systemic inflammatory 203 response syndrome and abnormal coagulation. Possible molecular effectors of COVID-19 disease

severity in EP6 are discussed in an accompanying study. Another endophenotype (EP5), while leading to unfavorable clinical trajectory during hospitalization, was instead associated with clear markers of cardiovascular disease, cardiovascular complications during hospitalization, and older age. The distribution of clinical laboratories in each endophenotype was sufficient to train an accurate prognostic model that could readily support future clinical care, since it only requires data from routine clinical laboratory results for prognosis.

210

211 The identification of endophenotypes was done systematically using robust consensus clustering 212 of aptamer expression levels in which the optimum number of clusters was determined 213 congruently using two well-established measures: AIC and BIC. The consensus clustering using 214 bootstrap sampling (1000 times) ensured identification of robust clusters that are not sensitive 215 to exclusion of some of the samples (20% randomly selected and excluded at each cycle). The 216 mean Rand-index between each of the 1000 subsampled clusterings and the final consensus 217 clustering was 0.823, reflecting a high degree of concordance and robustness. Moreover, 218 identifying the best number of clusters using AIC/BIC (both of which agreed with each other) 219 allowed us to reveal the patterns of the EPs directly from the data instead of imposing a pattern 220 onto it through human supervision. This is an important strength of the study that enabled us to 221 identify distinct molecular patterns of patients that could have remained undetected using other 222 traditional approaches.

223

Additionally, to improve the translational applicability of the EPs, we developed a prognostic model based only on measurements of conventional clinical laboratory blood markers to test the

226 generalizability of these endophenotypes to samples without measured aptamer data. 227 Characteristics of EPs predicted solely based on their blood markers were consistent with the 228 original EPs, suggesting that clinical blood markers could be used as surrogates for assignment of 229 these EPs to new patients and potentially automating identification of high-risk groups in the 230 clinic. This approach takes into account the effect of multiple blood variables simultaneously and 231 incorporates the full distribution of each variable. This is in contrast to the clinical laboratory 232 results that are automatically flagged as within or outside normal range, one variable at a time, 233 therefore increasing the clinical applicability of our model by leveraging a wider spectrum of 234 information to prognosticate patient outcomes.

235

236 Limitations and considerations

237 The data presented in this study comes from individuals participating in the BQC19, a prospective 238 observational cohort built to study COVID-19 in Québec (Canada) with its specific population 239 profile as reported previously (6). A chronological bias may also be present, as most of the 240 participants used for endophenotyping in this study were recruited during the first two waves of 241 the pandemic (Figure S1), prior to widespread vaccination in Québec and the appearance of the 242 Omicron variant and sub-variants. Therefore, some of the features of the identified 243 endophenotypes may change over the course of the pandemic. It will be essential to continue 244 longitudinal assessments of the molecular profiles to better understand the dynamic nature of host-pathogen interactions. It will also be interesting to compare the profiles of COVID-19 ARDS 245 246 to other viral-induced ARDS, to identify common as well as distinguishing features of these 247 conditions.

248

249 Conclusion

Respiratory infections represent an important challenge for respirologists and critical care physicians due to the heterogeneity of outcomes. Developing better ways to prognosticate poor outcomes is crucial in improving patients' care and survival. In this manuscript, we proposed a novel experimental approach that leverages detailed proteomic information but relies on routinely available information in the clinic for prognostication to favor translation that may find applications in many other diseases beyond COVID-19.

256

257 Methods:

258 Datasets and preprocessing

The Biobanque Québécoise de la COVID-19 (BQC19; www.guebeccovidbiobank.ca) is aimed at 259 260 coordinating the collection of patients' data and samples for COVID-19 related research. Data 261 and samples were collected from ten sites across the province of Québec (Canada) (6). BQC19 262 organizes the collected data, including clinical information and multi-omics experimental data, 263 before making it available in successive releases. For this study, we used the circulating proteome 264 determined using SOMAmers. Our main corpus of analysis consisted of n = 1,634 hospitalized 265 and SARS-CoV-2 positive patients (based on qRT-PCR) of BQC19. This included n = 731 patients 266 (Figure S1) for which both clinical and proteomic data was available as well as n = 903 patients 267 (Figure S6) for whom proteomic data was not available but whose clinical data contained 268 measurements for more than half (at least 11 out of 21) of the blood markers that we used as a 269 validation set for the prognostic model developed in this study.

270

271 We also obtained data (n = 731) corresponding to the circulating proteome measured between 272 April 2, 2020 and April 20, 2021 by a multiplex SOMAmer affinity array (SomaLogic, 4,985 273 aptamers) from BQC19. When measurements of the same patients but at different time points 274 were available, we used the one corresponding to the first time point. SomaScan is a 275 biotechnological protocol commercialized by the SomaLogic company (7). It relies on a set of 276 artificial aptamers linked to a fluorophore and each designed to bind a single protein. Once added 277 to the sample, the activity of each aptamer is measured through fluorescence and used to 278 approximate the expression level of the targeted protein. SomaScan protocol comprises several 279 levels of calibration and normalization to correct technical biases. Log2 and Z-score normalization 280 were performed on each aptamer separately in addition to the manufacturer's provided 281 normalized data (hybridization control normalization, intraplate median signal normalization, 282 and median signal normalization). Since the data was analyzed by SomaLogic in two separate 283 batches, we applied the z-score transformation separately to each batch, to reduce batch effects. 284 These additional transformations ensure that the measured values of different aptamers are 285 comparable and can be used in cluster analysis.

286

287 **Consensus agglomerative clustering**

Patients were clustered using agglomerative clustering with Euclidean distance and Ward's linkage (8, 9). To identify number of clusters k, we used the elbow method based on the AIC and BIC . More specifically, we calculated the AIC and BIC for clustering using k = 2, 3, ..., 20 and used the Kneedle algorithm (20) to identify the value of k corresponding to the "elbow", where

292	increasing the value of k does not provide much better modeling of the data. Kneedle identified
293	k = 6 as the number of clusters based on both AIC and BIC (Figure 1A).

294

295 Given the number of clusters in the data, we then used consensus clustering with sub-sampling 296 to obtain robust endophenotypes. We randomly sampled 80% of the patients 1000 times. Each 297 time, we used the agglomerative clustering above with k = 6 to identify clusters. Given these 1000 298 clusterings, we calculated the frequency of two patients appearing in the same cluster, when 299 both were present in the randomly formed dataset. We then performed one final agglomerative clustering of these frequency scores to identify the six endophenotypes (Figure S2A and Figure 300 301 1B).

302

303 Nearest-centroid predictor based on blood markers

304 In order to predict endophenotypes from blood tests, we developed a missing-value resilient 305 nearest-centroid classifier. We used the dataset of patients that were used to form the original 306 EPs (n = 731) as the training set and the dataset of patients that did not have proteome data as 307 the validation set (n = 903). First, we z-score normalized each of the 43 markers across all the 308 patients in the training set, one marker at a time. We then formed a marker signature (a vector 309 of length 43) for each EP. Each element of an EP's signature corresponds to the mean of the 310 corresponding marker across all patients of that EP.

311

312 To predict the EP label of each patient in the test set, we first z-score normalized their blood 313 marker measurements using the mean and standard deviation of the markers calculated from

314	the training set. Then, we calculated the cosine distance between each test patient's blood
315	marker profile and the centroids (excluding missing values) and identified the nearest EP as the
316	predicted EP (PEP) label of the patient.
317	
318	Statistics
319	Several non-parametric tests, including Mann–Whitney U test, Fisher's exact test, and
320	Spearman's rank correlation, were used in this study. Benjamini–Hochberg false discovery rate
321	(FDR) was used to adjust the p-values for multiple tests.
322	
323	Study approval
324	The study was approved by the Institutional Ethics Review Board of the "Centre intégré
325	universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean" (CIUSSS-SLSJ) affiliated
326	to the Université de Sherbrooke [protocol #2021-369, 2021-014 CMDO – COVID19].
327	
328	Acknowledgements
329	This work was made possible through open sharing of data and samples from the Biobanque
330	Québécoise de la COVID-19, funded by the Fonds de recherche du Québec - Santé, Génome
331	Québec, the Public Health Agency of Canada and, as of March 2022, the Ministère de la Santé et
332	des Services Sociaux du Québec. We thank all participants to BQC19 for their contribution. This
333	study was supported by the Fonds de recherche du Québec - Santé (FRQS)- Cardiometabolic
334	Health, Diabetes and Obesity Research Network (CMDO)- Initiative. This work was also supported
335	by Natural Sciences and Engineering Research Council of Canada (NSERC) grant RGPIN-2019-

- 336 04460 (AE). The authors also acknowledge the in-kind contribution of Roche Diagnostics, a
- 337 division of Hoffmann–La Roche Limited, which provided the reagents for the biomarker analyses
- 338 conducted on the BQC19 blood samples.
- 339
- 340 Conflict of Interests
- 341 The authors have declared that no conflict of interest exists.



343

Figure 1: Unsupervised consensus clustering of SARS-CoV-2 positive patients.

A) The elbow points (circles in red) of Akaike's Information Criteria (AIC) and Bayesian Information Criteria (BIC) curves versus number of clusters consistently corresponded to k=6 as the optimal number of clusters. B) The heatmap shows the expression of aptamers (rows) in each sample (columns). The dendrogram shows the identified endophenotypes. C) Characterization of samples based on sex at birth, highest world health organization (WHO) severity level achieved, intensive care unit (ICU) admission, ventilatory support, and oxygen therapy. For the last three rows, a sample colored "black" reflects a label of "yes".





Figure 2: Characterization of endophenotypes (EPs).

A) Enrichment or depletion of each EP in clinical variables (one cluster versus rest). Two-sided 355 356 Fisher's exact tests are used to calculate the p-values, which are corrected for multiple tests using 357 Benjamini–Hochberg false discovery rate (FDR). Gradients of blue show depletion, while 358 gradients of red show enrichment. FDR values above 0.05 are depicted as white. B) The number 359 of patients in each EP and the colors used to represent them in panels C, D, and E. C) Kaplan-360 Meier analysis of the time between patients' admission to the hospital and their admission to 361 intensive care unit (ICU) (or death if earlier) for each EP (Delta). D) Distribution of age in each EP. 362 E) Distribution of BMI in each EP. F) COVID-19 severity in each EP.

	Anemia: Yes -	20%	18%	13%	21%	41%	23%
	Bacteremia: Yes -	2%	2%	2%	7%	12%	13%
	Bronchiolitis: Yes -	0%	0%	1%	0%	0%	0%
- 10-2	Seizure: Yes -	1%	2%	1%	0%	0%	1%
- 10 ⁻⁴	Liver dysfunction: Yes -	10%	8%	10%	5%	7%	22%
- 10 ⁻⁶	Pleural effusion: Yes -	9%	5%	6%	3%	10%	7%
	Gastrointestinal haemorrhage: Yes -	4%	2%	1%	0%	0%	3%
- 10 ⁻⁸	Hyperglycemia: Yes -	14%	14%	21%	23%	27%	31%
- 10 ⁻¹⁰	Hypoglycemia: Yes -	6%	2%	2%	3%	3%	5%
	Acute kidney injury: Yes -	25%	18%	12%	16%	51%	50%
	Meningitis or encephalitis: Yes -	1%	0%	0%	0%	0%	3%
	Pancreatitis: Yes -	1%	0%	1%	0%	5%	3%
	Bacterial pneumonia: Yes -	16%	14%	16%	19%	25%	38%
Cryptoger	ic organizing pneumonia (COP): Yes -	0%	0%	1%	0%	0%	1%
	Viral pneumonia/pneumonitis: Yes -	49%	35%	34%	47%	51%	42%
	Pneumothorax: Yes -	1%	1%	1%	3%	0%	5%
	Rhabdomyolysis or myositis: Yes -	1%	0%	1%	0%	2%	4%
Acute Respira	tory Distress Syndrome (ARDS): Yes -	9%	14%	18%	25%	31%	50%
Other viral	infection during hospitalization: Yes -	2%	2%	1%	1%	2%	3%
Positive bacteri	al culture during hospitalization: Yes -	20%	16%	12%	16%	34%	31%
	Cardiovascular complications: Yes -	21%	17%	16%	21%	42%	39%
	Other complications: Yes -	40%	33%	38%	48%	58%	53%
		EP1	EP2	EP3	EP4	EP5	EP6

363

Figure 3: Frequency and significance of complications in different EPs.

The value in each cell shows the percentage of patients of that EP (column) that suffered from

the complication (row). The colors represent two-sided Fisher's exact test false discovery rate

367 (FDR, corrected for multiple tests). Red represents enrichment, while blue represents depletion.368 FDR values below 0.05 are shown as white.

WBC (Highest) (x 10^9/L)	9.3	8.9	10.2	10.6	10.5	14.8	F
Neutrophil (Highest) (relative %) -	77.6	79.7	81.1	83.4	82.9	89.2	
Lymphocyte (Lowest) (relative %) -	14.0	11.6	8.7	8.5	6.8	4.5	
Monocyte (Highest) (relative %) -	11.2	10.3	9.6	9.7	11.8	9.8	
Eosinophil (Highest) (relative %) -	1.9	1.7	1.1	1.0	2.0	2.5	
Basophil (Highest) (relative %) -	0.4	0.4	0.2	0.5	0.6	0.6	
Platelet (Lowest) (x 10^9/L) -	186	198	234	203	130	180	
Haemoglobin (Lowest) (g/L) -	116	118	118	116	81	100	
Urea (Highest) (mmol/L) -	7.3	7.0	7.8	7.7	19.9	16.4	
Creatinine (Highest) (umol/L) -	83	87	76	79	255	114	
Sodium Na+ (Highest) (mmol/L) -	142	141	142	142	142	146	
Potassium K+ (Highest) (mmol/L) -	4.4	4.4	4.5	4.5	4.9	4.9	
C-reactive protein (Highest) (U/L) -	77	87	102	124	94	160	
LDH (Highest) (U/L) -	333	344	394	418	372	589	
Albumin (Lowest) (g/L) -	31	31	30	30	27	25	
ALT (Highest) (U/L) -	35	40	53	65	29	100	
APTT (Highest) (sec) -	34	32	33	35	36	38	
INR (Highest) -	1.2	1.2	1.1	1.2	1.6	1.3	
Bilirubin (Highest) (umol/L) -	9.0	9.0	10.0	9.0	9.0	13.0	
Glucose (Highest) (mmol/L) -	8.0	7.5	8.4	8.6	11.6	11.5	
D-Dimer (Highest) (ug/L) -	974	938	1053	1002	1775	2083	
	EP1	EP2	EP3	EP4	EP5	EP6	

А

 -10^{-5} -10^{-10} -10^{-15} -10^{-20} -10^{-25}

FDR - 10⁻⁵ - 10⁻¹⁰ - 10⁻¹⁵ - 10⁻²⁰ - 10⁻²⁵

	-	
L		l
I		1
L		ļ

D						
Alpha-1 Antitrypsin (g/L) -	1.2	1.4	1.6	1.5	1.5	1.8
Anti-SARS-CoV-2 antibodies (U/mL) -	4.09	2.56	10.39	21.12	0.40	30.67
Alkaline phosphatase (U/L) -	50	62	55	53	72	63
Cancer antigen 125 (U/mL) -	8.9	9.5	8.8	8.3	13.0	12.8
Creatine Kinase (U/L) -	38	59	64	49	71	107
Creatine Kinase MB (ng/mL) -	0.86	0.88	1.07	0.90	1.82	1.61
Calcium (mmol/L) -	1.6	1.7	1.7	1.6	1.6	1.6
Cholesterol (mmol/L) -	2.4	2.8	2.7	2.5	2.4	2.6
Cystatin C (mg/L) -	0.76	0.82	0.82	0.83	2.42	1.17
Ferritin (ug/L) -	213	289	566	474	634	835
Growth/diff. factor-15 (pg/mL) -	2017	2176	2141	2136	7199	4454
Human Epididymis Protein 4 (pmol/L) -	81	73	105	98	482	233
Interleukine-6 (pg/mL) -	12	17	15	29	43	53
Brain natriuretic peptide 32 (pg/mL) -	140	91	140	198	2438	339
Procalcitonin (ng/mL) -	0.051	0.072	0.065	0.074	0.246	0.185
Phosphate (mmol/L) -	0.73	0.92	0.83	0.83	1.15	0.89
Free T4 (pmol/L) -	16	15	16	16	15	14
Triglycerides (mmol/L) -	1.00	1.08	1.29	1.14	1.10	1.53
Troponin T HS (ng/L) -	9.9	9.0	9.0	10.0	58.3	19.1
Vitamin B12 (pmol/L) -	360	373	423	441	564	581
Vitamin D (nmol/L) -	30	36	25	30	43	24
Soluble fms-like tyrosine kinase 1 (pg/mL) -	76	87	98	89	114	126
	EP1	EP2	EP3	EP4	EP5	EP6

Figure 4: Patterns of blood markers and Roche diagnostic markers in the endophenotypes (EPs). Heatmaps show the false discovery rate (FDR) values for two-sided one-vs-rest Mann–Whitney U tests for 21 blood markers (most extreme value during hospitalization) (A) and 22 Roche diagnostic markers (B) for each EP. FDR values below 0.05 are shown as white. The numerical values show the median value of the maker in each EP. Abbreviations used: WBC = white blood cells, LDH = lactate dehydrogenase, ALT = alanine aminotransferase, aPTT = activated partial thromboplastin time, INR = International Normalized Ratio.

- 377
- 378
- 379
- 380





388 Tables

		Cohort (n=731) No. (%)	EP1 (n=189) No. (%)	EP2 (n=130) No. (%)	EP3 (n=160) No. (%)	EP4 (n=75) No. (%)	EP5 (n=59) No. (%)	EP6 (n=118) No. (%)
	<45	17.0	18.0	21.5	21.2	16.0	6.8	10.2
• (45-65	34.9	31.7	34.6	43.1	36.0	18.6	36.4
Age (years)	>65	48.2	50.3	43.8	35.6	48.0	74.6	53.4
-	Unknown	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	<20	2.2	2.6	3.8	0.6	0.0	5.1	1.7
Body mass	20-25	11.8	11.6	14.6	12.5	4.0	18.6	9.3
index in	25-35	27.2	33.9	26.9	18.8	21.3	28.8	31.4
kg/m ²	>35	7.0	5.8	3.1	6.9	10.7	10.2	9.3
-	Unknown	51.8	46.0	51.5	61.3	64.0	37.3	48.3
Cour of hinth	Female	43.8	52.4	50.0	34.4	54.7	39.0	31.4
Sex at birth	Male	56.2	47.6	50.0	65.6	45.3	61.0	68.6
	Deceased	3.1	0.5	1.5	3.1	0.0	5.1	10.2
-	Severe	31.5	12.7	19.2	33.8	37.3	39.0	64.4
Severity	Moderate	51.2	65.1	56.9	47.5	58.7	52.5	22.0
-	Mild	11.5	19.6	17.7	13.1	1.3	1.7	0.8
-	Unknown	2.7	2.1	4.6	2.5	2.7	1.7	2.5
_	Yes	66.6	45.0	48.5	68.1	92.0	78.0	97.5
Oxygen therapy	No	22.8	45.0	38.5	11.2	5.3	13.6	1.7
-	Unknown	10.5	10.1	13.1	20.6	2.7	8.5	0.8
	Yes	65.1	43.4	47.7	68.1	86.7	74.6	96.6
Ventilatory	No	11.4	11.6	16.9	16.2	4.0	13.6	1.7
Sabbour -	Unknown	23.5	45.0	35.4	15.6	9.3	11.9	1.7
Admission to	Yes	32.0	12.2	20.0	30.6	30.7	37.3	77.1
intensive	No	65.8	84.7	77.7	66.2	68.0	62.7	22.0
care unit	Unknown	2.2	3.2	2.3	3.1	1.3	0.0	0.8

Table 1: Clinical and pathological characteristics of the BQC19's participants used in to identifyendophenotypes (EPs) in this study.

391

392

Table 2: Summary of the characteristics of each endophenotype.

In this table, High (Low), denoted as H (L) implies that the average value of the variable in the corresponding EP was significantly higher (lower) than the other EPs (considered together), while

397 N (Nondescript) implies that it was not significantly different.

398

Endophenotype	Age	Sex at birth	ВМІ	Blood markers
EP1	Н	F	Ν	High lymphocyte, Low neutrophil
EP2	Ν	Ν	L	High albumin, Low white blood cells
EP3	L	М	Ν	High platelet, Low creatinine
EP4	Ν	Ν	Ν	High lactate
EP5	Н	Ν	Ν	High creatinine, Low haemoglobin
EP6	Ν	М	Ν	High white blood cells, Low lymphocyte

399 Abbreviations used: H = High, L = Low, N = Nondescript, F = Female, M = Male

401 References

- Hull DL. Informal aspects of theory reduction. PSA: Proceedings of the biennial meeting
 of the philosophy of science association: Cambridge University Press; 1974. p. 653-670.
- Te Pas MFW, Madsen O, Calus MPL, Smits MA. The Importance of Endophenotypes to
 Evaluate the Relationship between Genotype and External Phenotype. International
 Journal of Molecular Sciences 2017; 18: 472.
- Blatti III C, Emad A, Berry MJ, Gatzke L, Epstein M, Lanier D, et al. Knowledge-guided
 analysis of "omics" data using the KnowEnG cloud platform. *PLoS biology* 2020; 18:
 e3000583.
- 4. Emad A, Ray T, Jensen TW, Parat M, Natrajan R, Sinha S, et al. Superior breast cancer
 411 metastasis risk stratification using an epithelial-mesenchymal-amoeboid transition gene
 412 signature. *Breast Cancer Research* 2020; 22: 74.
- Al-Hadrawi DS, Al-Rubaye HT, Almulla AF, Al-Hakeim HK, Maes M. Lowered oxygen
 saturation and increased body temperature in acute COVID-19 largely predict chronic
 fatigue syndrome and affective symptoms due to Long COVID: A precision nomothetic
 approach. Acta Neuropsychiatr 2022: 1-12.
- 417 6. Tremblay K, Rousseau S, Zawati MnH, Auld D, Chassé M, Coderre D, et al. The Biobanque
 418 québécoise de la COVID-19 (BQC19)—A cohort to prospectively study the clinical and
 419 biological determinants of COVID-19 clinical trajectories. *PloS one* 2021; 16: e0245031.
- 420 7. Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody E, et al. Aptamer-based multiplexed
 421 proteomic technology for biomarker discovery. *Nature Precedings* 2010: 1-1.
- 422 8. Ward Jr JH. Hierarchical grouping to optimize an objective function. *Journal of the*423 *American statistical association* 1963; 58: 236-244.
- 424 9. Murtagh F, Legendre P. Ward's Hierarchical Agglomerative Clustering Method: Which
 425 Algorithms Implement Ward's Criterion? *Journal of Classification* 2014; 31: 274-295.
- 426 10. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *Journal of* 427 *the American Statistical Association* 1958; 53: 457-481.
- 428 11. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamua M. Sequential
 429 measurement of IL-6 blood levels in patients with systemic inflammatory response
 430 syndrome (SIRS)/sepsis. *Cytokine* 2005; 29: 169-75.
- Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive
 protein, and procalcitonin in patients with COVID-19. *J Clin Virol* 2020; 127: 104370.

- 433 13. McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, et al. Liver injury in
 434 COVID-19 and IL-6 trans-signaling-induced endotheliopathy. *J Hepatol* 2021; 75: 647-658.
- 435 14. Ruscitti P, Berardicurti O, Di Benedetto P, Cipriani P, Iagnocco A, Shoenfeld Y, et al. Severe
 436 COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An
 437 Immunomodulatory Perspective to Alleviate the Storm. *Front Immunol* 2020; 11: 1130.
- Ding J, Hostallero DE, El Khili MR, Fonseca GJ, Milette S, Noorah N, et al. A networkinformed analysis of SARS-CoV-2 and hemophagocytic lymphohistiocytosis genes'
 interactions points to Neutrophil extracellular traps as mediators of thrombosis in COVID-*PLoS Computational Biology* 2021; 17: e1008810.
- 442 16. Greco M, Suppressa S, Lazzari RA, Sicuro F, Catanese C, Lobreglio G. sFlt-1 and CA 15.3 are
 443 indicators of endothelial damage and pulmonary fibrosis in SARS-CoV-2 infection. *Sci Rep*444 2021; 11: 19979.
- Corteville DC, Bibbins-Domingo K, Wu AH, Ali S, Schiller NB, Whooley MA. N-terminal proB-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with
 coronary disease: data from the heart and soul study. *Arch Intern Med* 2007; 167: 483-9.
- 44818.Adela R, Banerjee SK. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular449Diseases: A Translational Prospective. J Diabetes Res 2015; 2015: 490842.
- Pandey A, Patel KV, Vongpatanasin W, Ayers C, Berry JD, Mentz RJ, et al. Incorporation of
 Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According
 to the 2017 ACC/AHA High Blood Pressure Guideline: A Pooled Cohort Analysis. *Circulation* 2019; 140: 2076-2088.
- Satopaa V, Albrecht J, Irwin D, Raghavan B. Finding a "kneedle" in a haystack: Detecting
 knee points in system behavior. 31st international conference on distributed computing
 systems workshops: IEEE; 2011. p. 166-171.